CVS Beats Q2 Expectations and Raises 2026 Guidance, But Shares Drop on Soft 2027 Outlook
CVS Health reports strong Q2 results with $2.58 adjusted EPS and raises 2026 guidance, but shares fall on a muted 2027 outlook and cautious cost warnings.
/ 57 items
#XY Earnings Movers↓
Compass Pathways Shares Jump on Strong COMP360 Phase 3 Data and Clear Path to 2027 Launch
Compass Pathways reports strong Q2: Phase 3 wins for COMP360 in TRD, $433M cash, rolling NDA, and commercial launch planned for first half 2027.
Eli Lilly Raises 2026 Revenue Forecast as GLP-1 Drugs Fuel Record Growth
Eli Lilly beats Q2 estimates with revenue up 48% to $23B, driven by Mounjaro and Zepbound. Company raises full-year outlook to $85–87 billion.
FILSPARI Demand Soars: Travere Posts 96% Sales Growth and Strong FSGS Launch
Travere stock jumps as FILSPARI sales surge, beating forecasts and showing strong patient demand and future growth potential.
Novo Nordisk’s Guidance Raise Wasn’t Enough: The Lingering Challenges That Drove Shares Lower
Despite Q2 beat and raise, Novo shares dropped on flat 2026 outlook, DKK 6.3B impairment, ZEUS failure and fierce Lilly competition.
Oppenheimer Upgrades Inspire Medical to Outperform with $85 Target After Q2 Beat
Company raises 2026 guidance and launches cost-cutting plan.